Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01498354
Other study ID # TEO-TEM-2010-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2010
Est. completion date February 2012

Study information

Verified date April 2019
Source Corporacion Parc Tauli
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction: The usual surgical technique for large adenomatous tumors and rectal cancer is anterior resection of the rectum or abdominoperineal resection. These techniques are associated with high mortality and morbidity and with genitourinary dysfunctions.

To solve these problems, transanal endoscopic microsurgery (TEM) was designed. Through its 3-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge. It is associated with minimal morbidity and has few repercussions for anal continence.

The use of 2-D high definition cameras and screens obtains images of a similar quality to 3-D images. This means that from the surgical point of view the procedure known as TEO (transanal endoscopic operation) seems as practicable as classic TEM.

Main aim: To assess the effectiveness of 2-D high definition vision systems (TEO) versus conventional 3-D (TEM) in endoscopic surgery of rectal tumors, with respect to surgical facility, postoperative morbidity, quality of the surgical specimens, and cost.

Design: Prospective, controlled, randomized study of the efficacy of the use of 2-D high definition endoscopic systems versus 3-D (TEM) in transanal endoscopic surgery.

Disease studied: Rectal adenomas and adenocarcinomas "in situ" suitable for local surgery.

Main variable evaluated: Cost per procedure assuming similar surgical efficacy and equal postoperative morbidity.

Study population and total number of patients: Patients diagnosed with rectal tumor treated with curative intent (rectal adenomas and adenocarcinomas "in situ"). The total sample calculated for the trial was 36 patients, 18 in each group (TEO and TEM).

Timing and expected finish date: After approval by the CEIC, the expected date for the inclusion of the first patient was August 2010. The study is expected to last 18-24 months.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date February 2012
Est. primary completion date October 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Patients of either sex older than 18 years

- Rectal tumor identified as rectal adenoma by multifocal biopsy using colonoscopy, with endorectal ultrasound and magnetic resonance imaging findings of non-invasive tumor.

- Size of the tumor between 2 and 6 cm in maximum diameter.

- Tumor location, lower edge at least 2 cm from the anal verge, and upper edge at least 15 cm from the anal verge.

- ASA score more than III.

- intervention was performed under general anesthesia

Exclusion Criteria:

- Invasive adenocarcinoma shown in the final pathology study. "in situ" or intraepithelial adenocarcinomas are not excluded .

- Pregnant patients

- Patients with liver cirrhosis or blood dyscrasia.

- Patients who can not be administered under general anesthesia.

- Patients on antiplatelet or anticoagulation therapy who have not been properly prepared for surgery.

- Presence of two or more transanal endoscopic excisions in the same procedure.

- Informed consent not signed.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
2-D high definition vision systems, transanal endoscopic operation (TEO)
Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
Transanal endoscopic microsurgery (TEM)
Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge

Locations

Country Name City State
Spain Corporacion Sanitaria Universitaria Parc Tauli Sabadell Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cost per procedure assuming similar surgical efficacy and equal postoperative morbidity 30 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04651764 - Transanal Resection of Rectal Lesions With the ColubrisMX ELS System N/A
Completed NCT06158776 - Predicting Rectal Adenoma With Canceration and Investigating Mechanism Based on Multimodal MRI and Biochemical Model
Not yet recruiting NCT02579330 - Trial on Use of Coloshield in Transanal and Anal Surgery N/A